ClearPoint Neuro, Inc. (CLPT)

Insider Trading Filed: 2026-04-02

Key Insights

R. John Fletcher, a director of ClearPoint Neuro, Inc., acquired 1,270 shares of the company's common stock at $9.1 per share through the company's equity compensation plan.
The acquisition increases Fletcher's direct beneficial ownership to 117,932 shares, indicating ongoing confidence in the company.
Insider buying is often seen as a positive signal, suggesting Fletcher believes the company's stock is undervalued and has growth potential.

Insider Trading Filed: 2026-04-02

Key Insights

Pascal E. R. Girin, a director of ClearPoint Neuro, Inc., acquired 755 shares of the company's common stock at $9.1 per share, increasing his direct beneficial ownership to 98,206 shares.
The share acquisition was made pursuant to the company's Sixth Amended and Restated 2013 Incentive Compensation Plan, in payment of fees owed to Girin under the company's Non-Employee Director Compensation Plan.
This insider buying activity could signal the director's confidence in the company's future prospects and may be viewed positively by investors.

Insider Trading Filed: 2026-04-02

Key Insights

The reporting person, Timothy T. Richards, acquired 442 shares of ClearPoint Neuro, Inc. (CLPT) common stock on April 1, 2026 at $9.1 per share, increasing his direct beneficial ownership to 80,196 shares.
The share acquisition was made pursuant to the company's Sixth Amended and Restated 2013 Incentive Compensation Plan, as payment of fees owed to the reporting person under the company's Non-Employee Director Compensation Plan.
This insider transaction suggests the reporting person, who serves as a director, has confidence in the company's prospects and is aligning his interests with shareholders.

Insider Trading Filed: 2026-03-20

Key Insights

Joseph M. Burnett, the CEO and President of ClearPoint Neuro, Inc., has exercised 20,942 stock options at an exercise price of $3.24 per share, increasing his direct ownership of the company's common stock to 116,842 shares.
In addition to his direct ownership, Burnett indirectly owns 193,231 shares through the Joseph M. Burnett Trust, which he controls as the trustee.
The stock option exercise was part of a vesting schedule, with 20% of the total shares vesting on the first anniversary, 40% on the second anniversary, and the remaining 40% on the third anniversary of the July 9, 2020 grant date.

Annual Report Filed: 2026-03-17

Key Insights

ClearPoint Neuro has seen consistent growth in its Neurosurgery Navigation and Therapy segment, which generated $X million in revenue in 2025, up Y% from the prior year.
The company is expanding its product portfolio with the launch of new Capital Equipment and Software Systems and Software Products, which contributed $Z million in revenue in 2025.
ClearPoint Neuro has secured a $X million financing agreement with TPC Investments III LP, which will provide additional capital to support the company's growth initiatives.

Current Report Filed: 2026-03-17

Key Insights

ClearPoint Neuro reported strong financial results for the fourth quarter and full year 2025, indicating continued business momentum.
The company posted an updated investor presentation highlighting its strategic initiatives and growth opportunities.
The filing does not mention any material changes in leadership, agreements, or other significant events that would impact investors.

Insider Trading Filed: 2026-03-16

Key Insights

The reporting person, Danilo D'Alessandro, is the Chief Financial Officer of ClearPoint Neuro, Inc. and this Form 4 filing discloses his transaction of exercising 32,627 restricted stock units and the subsequent sale of 16,601 shares to cover tax withholding obligations.
The transaction indicates that the reporting person is holding a significant number of 119,285 shares of ClearPoint Neuro's common stock, which suggests his alignment with the company's long-term growth and success.
The timing of the transaction, occurring on March 12, 2026, suggests the reporting person is exercising his equity-based compensation as part of the company's regular compensation and incentive program.

Insider Trading Filed: 2026-03-16

Key Insights

The CEO and President of ClearPoint Neuro, Inc. (CLPT) exercised 84,829 restricted stock units and sold 43,161 shares to cover tax withholding obligations, indicating an ongoing belief in the company's long-term prospects.
The CEO's indirect beneficial ownership of 193,231 shares demonstrates a significant ownership stake and alignment with shareholder interests.
This transaction provides insight into the company's executive compensation structure and the CEO's confidence in the future performance of ClearPoint Neuro.

Insider Trading Filed: 2026-03-16

Key Insights

The reporting person, L. Jeremy Stigall, is the Chief Business Officer of ClearPoint Neuro, Inc. and exercised 30,995 restricted stock units, subsequently selling 15,151 shares to cover tax withholding obligations.
This transaction represents the scheduled vesting of Stigall's restricted stock units, which is a common practice for company insiders to gain ownership in the stock.
The transaction price of $11.53 per share suggests the shares were sold to cover tax obligations rather than an outright sale, indicating Stigall's continued confidence in the company's prospects.

Insider Trading Filed: 2026-03-16

Key Insights

Insider Mazin Sabra, the Chief Operating Officer, exercised 26,101 restricted stock units and sold 13,281 shares to cover tax withholding obligations, indicating ongoing commitment and confidence in the company.
The transaction represents a direct ownership change, with Sabra's direct ownership decreasing from 80,624 shares to 67,343 shares after the sale.
Restricted stock unit vesting and subsequent share sales are routine insider transactions, suggesting no major changes in Sabra's ownership position or the company's overall outlook.

Insider Trading Filed: 2026-03-13

Key Insights

The Chief Financial Officer of ClearPoint Neuro, Inc. (CLPT) exercised 4,145 restricted stock units, indicating their confidence in the company's prospects.
The CFO also sold 2,109 shares to cover applicable tax withholding obligations, suggesting they are managing their equity position in a planned manner.
The transaction represents a routine insider activity, as the restricted stock units were scheduled to vest on the reported date.

Insider Trading Filed: 2026-03-13

Key Insights

The reporting person, L. Jeremy Stigall, exercised 8,291 restricted stock units and had 3,224 shares withheld to cover tax obligations, indicating an ongoing commitment to the company.
Stigall's ownership of ClearPoint Neuro's common stock decreased from 95,862 shares to 92,638 shares after the reported transactions, suggesting a modest reduction in his stake.
The transactions were routine equity awards and tax withholding, reflecting standard compensation practices for a Chief Business Officer at the company.

Insider Trading Filed: 2026-03-10

Key Insights

The reporting person, Mazin Sabra, who is the Chief Operating Officer of ClearPoint Neuro, Inc. (CLPT), exercised 13,827 restricted stock units and sold 7,036 shares to cover tax withholding obligations.
This transaction aligns with Sabra's role as a key executive of the company and suggests continued ownership and commitment to CLPT.
The number of shares acquired and sold appears routine and in line with previous insider transactions, indicating no major changes in Sabra's ownership position.

Insider Trading Filed: 2026-03-10

Key Insights

Insider L. Jeremy Stigall, the Chief Business Officer, exercised 17,778 restricted stock units and sold 6,913 shares to cover tax withholding, indicating continued insider ownership in the company.
The timing of this transaction, on March 6, 2026, suggests the vesting and settlement of a previously awarded equity incentive compensation plan.
The net change in Stigall's direct ownership of 87,571 shares represents approximately 0.5% of the company's outstanding common stock, indicating a meaningful stake held by this key executive.

Insider Trading Filed: 2026-03-10

Key Insights

Danilo D'Alessandro, the Chief Financial Officer of ClearPoint Neuro, Inc. (CLPT), exercised 18,765 restricted stock units and sold 9,548 shares to cover tax withholding obligations.
This transaction represents the scheduled vesting of D'Alessandro's restricted stock units, indicating ongoing executive compensation and retention efforts at the company.
The Form 4 filing suggests a level of insider confidence as D'Alessandro maintains a significant direct ownership stake of 84,622 shares in the company.

Insider Trading Filed: 2026-03-05

Key Insights

Joseph M. Burnett, the CEO and President of ClearPoint Neuro, Inc. (CLPT), exercised 26,568 restricted stock units and sold 9,533 shares to cover tax withholding obligations, indicating some insider selling activity.
Burnett still holds 29,534 shares of CLPT stock directly and 193,231 shares indirectly through a trust, suggesting he maintains a significant ownership position in the company.
The transaction occurred on March 3, 2026, which was the scheduled vesting date for the restricted stock units.

Insider Trading Filed: 2026-03-05

Key Insights

Insider Danilo D'Alessandro, the Chief Financial Officer of ClearPoint Neuro, Inc., exercised 10,332 restricted stock units and sold 5,257 shares to cover tax withholding obligations, indicating a mix of insider activity.
The insider transaction suggests the CFO may have some confidence in the company's stock, but the partial sale could also indicate a desire to realize some gains.
Investors should monitor future insider trading activity to assess the management team's sentiment and conviction in the company's long-term prospects.

Insider Trading Filed: 2026-03-05

Key Insights

Insider L. Jeremy Stigall, the Chief Business Officer, exercised 8,856 restricted stock units and sold 4,506 shares to cover tax withholding, indicating ongoing participation in the company's equity compensation program.
The reported transactions suggest Stigall continues to hold a significant direct ownership stake of 76,706 shares in ClearPoint Neuro, Inc., aligning his interests with those of other shareholders.
The timing of these transactions, occurring on March 3, 2026, suggests routine equity award vesting and tax-related share dispositions, rather than any material change in Stigall's long-term ownership position.

Insider Trading Filed: 2026-03-05

Key Insights

Mazin Sabra, the Chief Operating Officer of ClearPoint Neuro, Inc. (CLPT), exercised 6,642 restricted stock units and sold 3,380 shares to cover tax withholding obligations, indicating ongoing executive participation in the company's equity program.
The transaction suggests Sabra's continued confidence in ClearPoint Neuro's long-term prospects, as he retained a direct ownership of 47,732 common shares following the reported transaction.
The equity award settlement and subsequent share sales are routine insider activities and do not appear to signal any significant change in Sabra's outlook or the company's overall performance.

Insider Trading Filed: 2026-02-26

Key Insights

Insider Joseph Burnett, the CEO and President, sold 19,951 shares of ClearPoint Neuro stock on February 25, 2026 at a weighted average price of $15.17 per share.
Burnett still holds 205,730 shares of ClearPoint Neuro stock, including 193,231 shares held indirectly through a trust.
The share sale was made pursuant to a pre-planned trading program under Rule 10b5-1, indicating it was part of a systematic selling strategy rather than a one-off transaction.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information